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Abstract The use of supplements during chemotherapy
is controversial, partly due to the potential effect of anti-
oxidants on reduced efficacy of chemotherapy-related
cytotoxicity. We examined supplement use among breast
cancer patients registered to a clinical trial (SWOG 0221)
before diagnosis and during treatment. Patients (n =
1,467) completed questionnaires regarding multivitamin
and supplement use at trial registration (baseline) to
capture use before diagnosis. Of these patients, 1,249
completed a 6-month followup questionnaire to capture use
during treatment. We examined the use of vitamins C, D,
E, B6, B12, folic acid, and calcium at these timepoints, as
well as physician recommendations regarding supplement
use. The use of vitamins C, E, folic acid, and calcium
decreased during treatment, while the use of vitamin B6
increased. Five hundred seventy four patients (51 %)
received no physician recommendations regarding supple-
ment use. Among the remaining 49, 10 % were advised not
to take multivitamins and/or supplements, 7 % were
advised to use only multivitamins, and 32 % received
recommendations to use multivitamins and/or supplements.
Among patients who took vitamin C before diagnosis,
those who were advised not to take supplements were [5
times more likely not to use of vitamin C during treatment
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than those not advised to stop use (OR = 5.27, 95 % CI
1.13–24.6). Previous non-users who were advised to take
a multivitamin were nearly 5 times more likely to use
multivitamins during treatment compared to those who
received no recommendation (OR = 4.66, 95 % CI
2.10–10.3). In this clinical trial for high-risk breast cancer,
supplement use generally decreased during treatment.
Upon followup from the clinical trial, findings regarding
supplement use and survival outcomes will better inform
physician recommendations for patients on adjuvant
chemotherapy.
Keywords Antioxidants  Dietary supplements 
Epidemiology  Breast cancer  Chemotherapy
Introduction
Dietary supplement use is widespread among adults in the
United States [1], and has been increasing over time [2].
Supplement use is especially prevalent among breast
cancer patients. In the Women’s Healthy Eating and
Living study, 58 % of the breast cancer survivors who
participated reported use of multivitamins with 46 and
42 % reporting use of vitamins E and C, respectively
[3, 4]. In the long Island breast cancer study project
(LIBCSP), 60 % of patients reported using antioxidant
supplements during adjuvant treatment [5]. Breast cancer
patients have also been shown to take dietary supplements
at dosages well above the recommended daily allowances
[4, 5].
There is controversy surrounding the use of antioxidant
supplements during therapy for cancer, particularly
because of their potentially negative effects on treatment
efficacy. As previously reviewed [6], a primary mechanism
of cytotoxicity for numerous chemotherapy agents, as well
as radiation therapy, is through generation of reactive
oxygen species (ROS), which damage and kill tumor as
well as normal cells. Because antioxidants can reduce ROS
and potentially reduce treatment efficacy, it has been rec-
ommended that physicians discourage their patients from
use of antioxidant supplements during treatment [7]. The
American Institute for Cancer Research states that ‘‘taking
dietary supplements containing levels of nutrients with
antioxidant properties much greater than the dietary ref-
erence intakes is not recommended during chemotherapy’’
[8, 9], and a 2005 Journal of Clinical Oncology commen-
tary from a large comprehensive cancer center discloses
that their patients are discouraged from taking supplements
during cancer treatment [10]. However, there are also
reports that antioxidants may reduce chemotherapy-
induced neurotoxicity and cardiotoxicity [6]. In addition, in
the life after cancer epidemiology (LACE) Study, breast
cancer patients frequently using vitamin C and vitamin E
had fewer recurrences and a reduced risk of mortality, but
an increased risk of death with frequent carotenoid use
[11].
Although supplement use appears to be common among
cancer patients, many patients do not discuss supplement
use with physicians. Estimates of percentages of patients
who report supplement use to their physicians range from
as low as 33 % to up to 82 % of patients [12–15]. In
addition, studies have indicated that the extent to which
health care providers communicate with patients about
supplement use is low with lack of confident knowledge on
the subject a major contributing factor [16, 17].
In this report, we present the characteristics of patients
enrolled in an observational study ancillary to a large
cooperative group therapeutic trial for women with high-
risk breast cancer. With data collected regarding previous
habits, use at registration, and again following completion
of treatment, this trial provides an ideal basis for examining
the use of vitamin supplements before diagnosis and during
chemotherapy, and the extent to which discussions with
patients’ physicians influenced patterns of usage during
treatment.
Methods
Patients
This study was conducted ancillary to a North American
Breast Cancer Group phase III trial (S0221) led by
SWOG, formerly Southwest Oncology Group. Eligibility
criteria for S0221 included confirmed diagnosis of oper-
able Stage II or III invasive breast cancer with known
estrogen or progesterone receptor status, high-risk status
based on tumor size or nodal involvement, a history of
modified radical mastectomy or local excision of all
tumors plus axillary node dissection or sentinel node
resection, and no previous history of chemotherapy or
radiation. Criteria also included normal blood work, age
18?, Zubrod performance status of 0–2, as well as a
medical history free of heart failure, angina, HIV, and
previous malignancies.
As shown in Fig. 1, patients enrolled in the trial were
randomized to four treatment arms. Each arm utilized the
same 3 drugs, but followed a different treatment schedule.
Patients received either doxorubicin plus cyclophospha-
mide every 2 weeks with pegfilgrastim support, or weekly
doxorubicin plus daily cyclophosphamide with filgrastim
support. Patients then received either 12 cycles of weekly
paclitaxel or paclitaxel every 2 weeks with pegfilgrastim
support for 6 cycles.
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This ancillary study regarding effects of lifestyle factors
on treatment outcomes was described in the therapeutic
consent for the trial, and informed consent included per-
mission to contact the patient. Upon agreement to partici-
pate, patients’ contact information was forwarded to
research study staff for followup with the potential par-
ticipants. This study ancillary to S0221 was approved by
the Institutional Review Board at Roswell Park Cancer
Institute, and at all participating institutions that enrolled
patients.
Study design
The long-term goal of this prospective ancillary study, the
diet, exercise, lifestyle, and cancer prognosis (DELCaP)
study, is to determine if habits and practices before and
during chemotherapy have any impact on treatment out-
comes, including treatment-related toxicities as well as
recurrence and survival. For this purpose, patients are con-
tacted at registration to the trial, the DELCaP study is
described in more detail, and a questionnaire is sent to the
participants. This baseline questionnaire gathers data on race
and ethnicity, menopausal status, height and weight, histo-
ries of smoking, alcohol consumption, and physical activity.
A 110-item Food Frequency Questionnaire and detailed data
on use of vitamins and supplements are also collected via
questions adapted from the VITAL study, which has been
extensively validated [18]. Participants are asked to gather
all multivitamins and supplements they are taking. For
multivitamins, patients may choose from a predefined list of
popular brands of multivitamin (Centrum, etc.) or may fill in
the specific brand they use, as well as the number of days of
use and the number of years taken in the past 10. Patients are
then queried for dosages of select multivitamin components.
For individual supplement use, frequency of use and daily
dose are recorded.
At 6 months after registration to the trial, when che-
motherapy should be completed, a second questionnaire is
mailed to participants. This questionnaire has the same
general format as the first, and updates lifestyle factors and
supplement use during treatment. It also includes a section
on recommendations received from the patient’s physi-
cians, and queries if the use of vitamins and supplements
during treatment was discussed and if the participants’
doctors made any recommendations. If recommendations
were received, patients are further queried regarding sug-
gestions (Fig. 2). Additional questionnaires are sent
annually soliciting the same information on lifestyle fac-
tors for eventual analysis in relation to recurrence and
survival.
Stage II and III Breast Cancer
Randomization
Arm 1
AC + PEGG x 6 cycles
Followed by 
q 2 wk T + PEGG x 6
Arm 2
AC + G x 15 weeks
Followed by 
q 2 wk T + PEGG x 6
Arm 3
AC + PEGG x 6 cycles
Followed by
Weekly T x 12
Arm 4
AC + G x 15 weeks
Followed by
Weekly T x 12
A=doxorubicin; C=cyclophosphamide; G=filgrastim; PEGG=pegfilgrastim; T=paclitaxel
Fig. 1 Design of SWOG 0221,
a trial for women with high-risk
breast cancer A doxorubicin,
C cyclophosphamide,
G filgrastim, PEGG
pegfilgrastim, T paclitaxel
Fig. 2 Question at completion
of chemotherapy regarding
physician recommendations
on supplement use during
treatment
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All questionnaires were entered twice by different data
entry personnel. This analysis includes 1,467 participants
who completed the baseline questionnaire; of these women,
we include data from 1,249 patients who also completed
the 6-month questionnaire. Two hundred eighteen partici-
pants withdrew from the study between the first question-
naire and the second questionnaire. These participants were
younger, less likely to be non-Hispanic white, were more
likely to have smoked, and had lower education.
Statistical analysis
The focus of this analysis is on use of vitamin supplements
before diagnosis and during treatment for breast cancer, and
in relation to physician recommendations. In the first ques-
tionnaire, patients were asked if they took supplements before
breast cancer diagnosis and/or, if they took supplements after
diagnosis (No; Yes, but less than once a week; Yes, at least
once a week). In the second questionnaire, participants were
asked if they took supplements during treatment. Those who
responded that they used supplements at least once per week
were classified as ‘‘users.’’ ‘‘Non-users’’ were those who did
not use at all, or used less than once per week. Because of the
low rates of use of other supplements, we present data only on
supplements with at least 10 % use at any time point. For all
analyses presented, we compared supplement use before
diagnosis to supplement use during treatment. Although
physician recommendations were not queried until the second
questionnaire, it is possible that physician recommendations
at diagnosis influenced supplement use during the period
between diagnosis and treatment. Thus, we compared use
before diagnosis and 6 months following entry into the trial.
Answers regarding physician recommendations were
categorized into ‘‘No recommendation,’’ ‘‘Do not use
vitamins and/or supplements during treatment,’’ ‘‘Use a
multivitamin only,’’ and ‘‘Use vitamins and supplements
during and after treatment.’’ Participants also had the
option to write in their physician’s recommendations,
instead of choosing from the predefined list. These answers
were hand-coded and grouped into one of the first three
categories. Of these, written answers from 115 participants
could not be classified into any of the categories.
For each supplement, participants were stratified by use
before diagnosis into baseline users and non-users. For
baseline users, unconditional logistic regression was used
to estimate odds ratios (OR) and 95 % confidence intervals
(CI) for the association between discontinuing use during
treatment and physician recommendations. Analogous
analyses for baseline non-users were conducted to model
the association between beginning use during treatment
and physician recommendations. Self-reported height and
usual weight before diagnosis were used to compute body
mass index (BMI) in kilograms/meters2. ORs and 95 % CIs
were calculated and adjusted for age at completion of the
first questionnaire, BMI, race/ethnicity, education level,
menopausal status, and smoking status (never/former/cur-
rent). All analyses were conducted by SAS 9.2.
Results
The baseline characteristics of 1,467 breast cancer patients
who completed the first questionnaire are shown in
Table 1. The mean age at baseline was 51 years (range:
23–80 years); 80 % of participants identified themselves
as non-Hispanic white and the majority of patients (71 %)
were overweight or obese. Slightly more than half were
postmenopausal. More than half (56 %) were never
smokers, 72 % had at least some college, and the majority
were married or living as married (73 %).
Supplements with usage of at least 10 % of the study
population either before diagnosis, or during treatment for
breast cancer, are displayed in Table 2. Multivitamins were
the supplements used most frequently with 48 % use before
diagnosis and 43 % use during treatment. Other supplements
that showed decreases in use during treatment included
vitamin C (20 % before diagnosis vs. 12 % during treat-
ment), vitamin E (15 vs. 6 %), folic acid (10 vs. 8 %), cal-
cium (34 vs. 28 %), fish oil, EPA, omega-3, flaxseed or cod
liver oil (22 vs. 12 %), and glucosamine (13 vs. 7 %).
Compared to before diagnosis, vitamin B6 use increased
during treatment (10 vs. 19 %).
Average supplement doses per day before diagnosis and
during breast cancer treatment are presented in Table 3.
After diagnosis and during treatment, vitamin D use
increased overall among those women in the middle and
highest categories of use with a concomitant decrease in
the lowest category of use. As expected, use of higher
doses of vitamin B6 (13? mg/day) increased markedly
during treatment, from 50 % before diagnosis to 87 %
during treatment. While overall use of B12 decreased
slightly between during breast cancer treatment, the per-
centage of high average daily dosage (24? lg/day)
increased from 67 % before diagnosis to 84 % during
treatment. Calcium use was largely unchanged from before
diagnosis to during treatment. Iron intake increased during
treatment in the lowest and highest categories, but
decreased for the middle category. There were no clear
trends for vitamins C and E.
Table 4 shows data collected from the 2nd questionnaire
administered at 6 months related to physician recommenda-
tions regarding supplement use. Five hundred seventy four
patients (51 %) received no recommendation (either due to no
discussion of supplement use with their doctors, or did discuss,
but received no specific recommendations). Among the
remaining 560 participants who did receive recommendations,
906 Breast Cancer Res Treat (2013) 137:903–913
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112 received recommendations not to take multivitamins and/
or supplements (10 %), 80 received recommendations to use
only multivitamins (7 %), and 368 received recommendations
to use multivitamins and/or supplements (32 %).
Multivitamin and supplement use during treatment
among baseline users
Multivitamin and supplement use during treatment was
compared to use before diagnosis in relation to physician
recommendations with the reference group comprised of
those receiving no recommendations. Models for baseline
multivitamin and supplement users adjusted for age at
baseline alone and additionally adjusted for BMI at base-
line, race/ethnicity, education level, menopausal status, and
smoking status are presented in Table 5. Among those
using multivitamins at least once per week at baseline,
patients receiving recommendations not to take multivita-
mins and/or supplements were 45 times more likely to
reduce multivitamin use to less than once per week during
treatment, compared to those receiving no recommenda-
tions (adjusted odds ratio (aOR) = 45.0, 95 % CI
10.6–191). Patients who were advised to use multivitamins
only were less likely to decrease use than those receiving
no recommendations (aOR = 0.21, 95 % CI 0.08–0.6), as
were patients receiving recommendations to use multivi-
tamins and/or supplements (aOR = 0.46, 95 % CI 0.29–
0.72).
Among those using vitamin C supplements at least
once per week at baseline, all patients receiving recom-
mendations not to take multivitamins and/or supplements
decreased use of vitamin C to less than once per week.
Patients who were told to use multivitamins only were
over 5 times more likely to decrease use of vitamin C,
compared to those receiving no recommendations
(aOR = 5.27, 95 % CI = 1.13–24.6). Compared to those
receiving no advice, participants receiving recommenda-
tions to use multivitamins and/or supplements during
treatment were less likely to decrease vitamin C use to
less than once per week although this difference was not
statistically significant (aOR = 0.72, 95 % CI = 0.37–
1.39).
Among those using vitamin E supplements at least once
per week at baseline, all patients receiving recommenda-
tions not to take multivitamins and/or supplements
decreased use of vitamin E to less than once per week.
Those receiving recommendations to use multivitamins
only were 3.5 times as likely to decrease vitamin E use to
less than once per week compared to those receiving no
recommendations (aOR = 3.52, 95 % CI 0.40–31.3).
Patients receiving recommendations to use multivitamins
and/or supplements during treatment were less likely to
decrease use of vitamin E to less than once per week than
those receiving no recommendations (aOR = 0.48, 95 %
CI 0.20–1.17).
Use of the other supplements assessed showed similar
trends in patterns of use although there were small numbers
for some subgroups. Fish oil and glucosamine users at
baseline, in particular, who received recommendations to
not use vitamins or supplements were much more likely to
stop usage, compared to those receiving no recommenda-
tion (aOR = 25.3, 95 % CI 3.30–195; aOR = 12.3, 95 %
CI 1.48–102, respectively).
Table 1 Characteristics of 1,467 DELCaP participants
Characteristic N (%)
Age
\35 63 (4.3)
35–39 109 (7.4)
40–44 195 (13.3)
45–49 276 (18.8)
50–54 277 (18.9)
55–59 225 (15.3)
60–64 174 (11.9)
65–69 100 (6.8)
C70 48 (3.3)
Race
Non-hispanic white 1,176 (80.2)
Hispanic 65 (4.4)
Black/African American 104 (7.1)
Other 122 (8.3)
BMI
Underweight (B18.5) 12 (0.8)
Normal (18.5–24.9) 412 (28.4)
Overweight (25–29.9) 469 (32.4)
Obese (C30) 556 (38.4)
Menopausal status
Premenopausal 686 (46.8)
Postmenopausal 781 (53.2)
Smoking history
Never smokers 806 (55.5)
Former smokers 461 (31.7)
Current smokers 186 (12.8)
Education
Grade school or some high school 97 (6.6)
High school graduate or GED 311 (21.3)
Some college or technical school 522 (35.8)
College graduate 325 (22.3)
Advanced degree 205 (14.0)
Marital status
Married or living as married 1,067 (73.1)
Widowed 68 (4.6)
Separated or Divorced 236 (16.2)
Single 89 (6.1)
Breast Cancer Res Treat (2013) 137:903–913 907
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Multivitamin and/or supplement use during treatment
among non-users
Analogous models for baseline non-users of multivitamins
and/or supplements are presented in Table 6. Multivitamin
use during treatment among previous non-users increased
among those whose physicians recommended multivitamin
use only during treatment (aOR = 4.66, 95 % CI
2.10–10.3). Few participants who were non-users of vita-
min C or vitamin E at baseline began using these vitamins
Table 2 Supplement use
before and during breast cancer
treatment
a McNemar’s test comparing the
differences in use before and during
treatment
Supplement use before diagnosis Supplement use during treatment Total Pa
No Yes
N (%) N (%) N (%)
Multivitamin
No 510 (41.2) 133 (10.7) 643 (51.9) 0.0009
Yes 193 (15.6) 402 (32.5) 595 (48.1)
Total 703 (56.8) 535 (43.2) 1,238 (100)
Vitamin C
No 931 (75.2) 62 (5.0) 993 (80.2) \.0001
Yes 160 (12.9) 85 (6.9) 245 (19.8)
Total 1,091 (88.1) 147 (11.9) 1,238 (100)
Vitamin D
No 795 (64.2) 155 (12.5) 950 (76.7) 0.1229
Yes 129 (10.4) 160 (12.9) 289 (23.3)
Total 924 (74.6) 315 (25.4) 1,239 (100)
Vitamin E
No 1,005 (81.2) 42 (3.4) 1,047 (84.6) \.0001
Yes 154 (12.4) 37 (3.0) 191 (15.4)
Total 1,159 (93.6) 79 (6.4) 1,238 (100)
Vitamin B6
No 933 (75.4) 186 (15.0) 1,119 (90.4) \.0001
Yes 69 (5.6) 50 (4.0) 119 (9.6)
Total 1,002 (80.9) 236 (19.1) 1238 (100)
Folic Acid
No 1,051 (84.8) 62 (5.0) 1,113 (89.8) 0.0231
Yes 90 (7.3) 37 (3.0) 127 (10.2)
Total 1,141 (92) 99 (8) 1,240 (100)
Vitamin B12
No 999 (80.5) 82 (6.6) 1,081 (87.1) 0.2622
Yes 97 (7.8) 63 (5.1) 160 (12.9)
Total 1,096 (88.3) 145 (11.7) 1,241 (100)
Calcium
No 695 (56.0) 119 (9.6) 814 (65.6) \.0001
Yes 198 (16.0) 229 (18.4) 427 (34.4)
Total 893 (72) 348 (28) 1,241 (100)
Fish oil, EPA, omega-3, flaxseed or cod liver oil
No 907 (73.5) 47 (3.8) 954 (77.3) \.0001
Yes 172 (13.9) 108 (8.8) 280 (22.7)
Total 1,079 (87.4) 155 (12.6) 1,234 (100)
Glucosamine
No 1,059 (85.7) 18 (1.5) 1,077 (87.1) \.0001
Yes 97 (7.8) 62 (5.0) 159 (12.9)
Total 1,156 (93.5) 80 (6.5) 1,236 (100)
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during treatment (6 and 5 %, respectively), regardless
of recommendations received. For non-users of vitamin C
at baseline, participants receiving recommendations to
use vitamins and supplements during treatment were twice
as likely to use vitamin C during treatment (aOR = 1.82,
95 % CI 0.99–3.33); similar associations were observed
for vitamin E (aOR = 4.59, 95 % CI 2.10–10.0). Baseline
non-users of vitamin D receiving recommendations to use
vitamins and supplements were nearly four times more
likely to start vitamin D use than those receiving no rec-
ommendation (aOR = 3.86, 95 % CI 2.55–5.86). Similar
associations were observed in vitamins B6 and B12
(aOR = 6.39, 95 % CI 4.24–9.62; aOR = 5.10, 95 % CI
2.78–9.37, respectively).
Discussion
Our analyses of multivitamin and supplement use during
chemotherapy by women enrolled in this clinical trial for
high-risk breast cancer indicate that, in general, supplement
use decreased during chemotherapy. However, use of
vitamin B6 increased, and while the percentage of vitamin
B12 users decreased slightly, more users reported vitamin
B12 use at a high dosage during treatment than before
diagnosis, perhaps to alleviate side effects of chemotherapy
including neuropathy and anemia. Use of vitamin D also
increased during treatment.
Supplement use in our study differed from previously
published results. It has been reported that approximately
45–80 % of breast cancer patients in the United States use
antioxidant supplements, including during treatment [19].
In the LIBCSP, 60.5 % of breast cancer patients reported
using supplements during treatment, and 38 % reported
using antioxidants during chemotherapy [5]. Of antioxidant
users, 69 % used doses higher than those contained in a
multivitamin. In our study of participants in a Cooperative
Group clinical trial, the use of supplements was much
lower at baseline (20 % used vitamin C at least once per
week, 15 % used vitamin E at least once per week) and
particularly lower during the course of chemotherapy
(12 % used vitamin C at least once per week, 8 % used
vitamin E at least once per week). This unexpected finding
of low use at baseline could be due to temporal changes in
awareness with growing publicity and recommendations
that supplements may reduce treatment efficacy. The
source populations may differ as well. Participants in both
the LIBCSP and LACE studies were older on average than
participants in our study (58.3 and 56.3 years versus 51.3,
respectively) [5, 11]. Women were enrolled onto S0221 at
sites throughout the country, from large metropolitan
cancer centers to community oncology group programs in
more rural areas, which may suggest that our sample is
more representative of the general population in the U.S.
Supplement use may be lower because the patients in this
study had high-risk breast cancer, and may be less willing
to use something with unknown effects on cancer therapy.
Despite the body of data from laboratory and preclinical
studies demonstrating that supplements may interfere with
chemotherapeutic efficacy, it is still unclear if use of sup-
plements during treatment has any effect on therapeutic
Table 3 Average supplement dose per day before and during breast
cancer treatment
Supplement Time period
Before diagnosis During treatment
N (%) N (%)
Vitamin C (mg/day)
\75 19 (8) 15 (10.3)
75–750 142 (59.9) 81 (55.9)
750? 76 (32.1) 49 (33.8)
Vitamin D (lg/day)
\15 147 (52.3) 137 (44.9)
15–150 129 (45.9) 158 (51.8)
150? 5 (1.8) 11 (3.6)
Vitamin E (mg/day)
\15 1 (0.6) 4 (5.1)
15–150 64 (36.8) 29 (37.2)
150? 109 (62.6) 45 (57.7)
Vitamin B6 (mg/day)
\1.3 3 (2.8) 1 (0.5)
1.3–13 51 (47.7) 27 (12.3)
13? 53 (49.5) 191 (87.2)
Folic acid (lg/day)
\400 38 (34.2) 28 (30.1)
400? 73 (65.8) 65 (69.9)
Vitamin B12 (lg/day)
\2.4 0 0
2.4–24 47 (33.3) 22 (15.9)
24? 94 (66.7) 116 (84.1)
Calcium (mg/day)
\1000 265 (65.4) 232 (66.1)
1000? 140 (34.6) 119 (33.9)
Table 4 Patient-reported physician recommendations on vitamin
and supplement use during treatment
Physician recommendation N (%)
No recommendation 574 (50.6)
Do not use vitamins or supplements during treatment 112 (9.9)
Use a multivitamin only 80 (7.1)
Use vitamins and supplements during and after treatment 368 (32.4)
Unable to be classified 115
Breast Cancer Res Treat (2013) 137:903–913 909
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Table 5 Odds of discontinuing supplement use during treatment among baseline multivitamin and antioxidant supplement users, according to
physician recommendations
Physician advice Usage during treatmenta
% Who stop use ORb (95 % CI) ORc (95 % CI)
Multivitamin supplement use [1/week at baseline (N = 542)
No recommendation 33 % (81/243) 1.0 (ref) 1.0 (ref)
Do not use vitamins or supplements 96 % (47/49) 45.0 (10.6–191) 44.7 (10.5–190)
Use a multivitamin only 10 % (5/49) 0.21 (0.08–0.56) 0.22 (0.08–0.60)
Use vitamins and supplements 18 % (37/201) 0.44 (0.28–0.69) 0.46 (0.29–0.72)
Vitamin C supplement use [1/week at baseline (N = 214)
No recommendation 60 % (55/91) 1.0 (ref) 1.0 (ref)
Do not use vitamins or supplements 100 % (28/28) NA NA
Use a multivitamin only 91 % (20/22) 5.99 (1.31–27.5) 5.27 (1.13–24.6)
Use vitamins and supplements 51 % (37/73) 0.69 (0.36–1.29) 0.72 (0.37–1.39)
Vitamin D supplement use [1/week at baseline (N = 259)
No recommendation 47 % (53/112) 1.0 (ref) 1.0 (ref)
Do not use vitamins or supplements 72 % (18/25) 2.76 (1.06–7.24) 2.61 (0.97–6.99)
Use a multivitamin only 58 % (11/19) 1.48 (0.54–4.08) 1.39 (0.48–3.99)
Use vitamins and supplements 36 % (37/103) 0.66 (0.38–1.16) 0.65 (0.37–1.16)
Vitamin E supplement use [1/week at baseline (N = 169)
No recommendation 79 % (59/75) 1.0 (ref) 1.0 (ref)
Do not use vitamins or supplements 100 % (21/21) NA NA
Use a multivitamin only 94 % (16/17) 3.74 (0.45–30.8) 3.52 (0.40–31.3)
Use vitamins and supplements 70 % (39/56) 0.58 (0.26–1.30) 0.48 (0.20–1.17)
Vitamin B6 supplement use [1/week at baseline (N = 102)
No recommendation 62 % (26/42) 1.0 (ref) 1.0 (ref)
Do not use vitamins or supplements 90 % (9/10) 5.50 (0.62–49.1) 11.0 (0.95–126)
Use a multivitamin only 75 % (9/12) 1.06 (0.22–5.00) 1.86 (0.25–14.0)
Use vitamins and supplements 42 % (16/38) 0.36 (0.14–0.93) 0.30 (0.09–0.98)
Folic acid supplement use [1/week at baseline (N = 111)
No recommendation 72 % (31/43) 1.0 (ref) 1.0 (ref)
Do not use vitamins or supplements 100 % (13/13) NA NA
Use a multivitamin only 89 % (8/9) 3.01 (0.33–27.1) 3.04 (0.30–31.2)
Use vitamins and supplements 61 % (28/46) 0.65 (0.26–1.60) 0.66 (0.24–1.80)
Vitamin B12 supplement use [1/week at baseline (N = 143)
No recommendation 58 % (36/62) 1.0 (ref) 1.0 (ref)
Do not use vitamins or supplements 91 % (10/11) 7.48 (0.88–63.2) 7.83 (0.91–67.1)
Use a multivitamin only 64 % (7/11) 1.01 (0.25–4.03) 1.17 (0.27–5.11)
Use vitamins and supplements 56 % (33/59) 0.89 (0.43–1.87) 0.87 (0.40–1.91)
Calcium supplement use [1/week at baseline (N = 388)
No recommendation 53 % (87/165) 1.0 (ref) 1.0 (ref)
Do not use vitamins or supplements 83 % (34/41) 4.22 (1.77–10.1) 4.15 (1.70–10.1)
Use a multivitamin only 47 % (16/34) 0.78 (0.37–1.64) 0.93 (0.43–2.00)
Use vitamins and supplements 33 % (49/148) 0.44 (0.28–0.70) 0.48 (0.30–0.77)
Fish oil, EPA, omega-3, flaxseed, or cod liver oil use [1/week at baseline (N = 242)
No recommendation 57 % (64/113) 1.0 (ref) 1.0 (ref)
Do not use vitamins or supplements 97 % (31/32) 24.5 (3.22–187) 25.3 (3.30–195)
Use a multivitamin only 67 % (12/18) 1.66 (0.57–4.81) 1.47 (0.49–4.37)
Use vitamins and supplements 47 % (37/79) 0.72 (0.40–1.29) 0.72 (0.39–1.33)
Glucosamine supplement use [1/week at baseline (N = 142)
No recommendation 58 % (35/60) 1.0 (ref) 1.0 (ref)
Do not use vitamins or supplements 95 % (19/20) 11.8 (1.47–95.1) 12.3 (1.48–102)
Use a multivitamin only 73 % (8/11) 1.77 (0.42–7.50) 1.64 (0.37–7.22)
Use vitamins and supplements 47 % (24/51) 0.60 (0.28–1.30) 0.61 (0.27–1.36)
a Continue use defined as those consuming the supplement C once per week; Stop use are those consuming the supplement \ once per week
b Adjusted for age at baseline
c Adjusted for age at baseline, body mass index at baseline, race/ethnicity, education, menopausal status, and smoking status
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Table 6 Odds of supplement usage during treatment among non-users of multivitamin and antioxidant supplements at baseline, according to
physician recommendations
Physician advice Usage during treatmenta ORb (95 % CI) ORc (95 % CI)
% Who start use
Multivitamin supplement non-users (N = 583)
No recommendation 14 % (45/327) 1.0 (ref) 1.0 (ref)
Do not use vitamins or supplements 8 % (5/62) 0.55 (0.21–1.43) 0.54 (0.21–1.44)
Use a multivitamin only 43 % (13/30) 4.74 (2.15–10.4) 4.66 (2.10–10.3)
Use vitamins and supplements 37 % (61/164) 3.70 (2.37–5.79) 3.59 (2.28–5.66)
Vitamin C supplement non-users (N = 910)
No recommendation 5 % (23/475) 1.0 (ref) 1.0 (ref)
Do not use vitamins or supplements 4 % (3/84) 0.74 (0.22–2.54) 0.87 (0.25–3.03)
Use a multivitamin only 3 % (2/58) 0.70 (0.16–3.06) 0.69 (0.16–3.05)
Use vitamins and supplements 9 % (26/293) 1.92 (1.07–3.43) 1.82 (0.99–3.33)
Vitamin D supplement non-users (N = 866)
No recommendation 10 % (44/454) 1.0 (ref) 1.0 (ref)
Do not use vitamins or supplements 5 % (4/87) 0.46 (0.16–1.33) 0.47 (0.16–1.34)
Use a multivitamin only 10 % (6/61) 1.03 (0.42–2.53) 0.93 (0.38–2.31)
Use vitamins and supplements 30 % (79/264) 4.08 (2.71–6.15) 3.86 (2.55–5.86)
Vitamin E supplement non-users (N = 956)
No recommendation 2 % (9/493) 1.0 (ref) 1.0 (ref)
Do not use vitamins or supplements 3 % (3/91) 1.75 (0.46–6.61) 1.73 (0.45–6.64)
Use a multivitamin only 0 % (0/63) NA NA
Use vitamins and supplements 9 % (27/309) 5.18 (2.4–11.2) 4.59 (2.10–10.0)
Vitamin B6 supplement non-users (N = 1023)
No recommendation 7 % (38/526) 1.0 (ref) 1.0 (ref)
Do not use vitamins or supplements 15 % (15/102) 2.26 (1.19–4.29) 2.40 (1.25–4.59)
Use a multivitamin only 7 % (5/67) 1.04 (0.39–2.73) 0.98 (0.37–2.60)
Use vitamins and supplements 33 % (109/328) 6.41 (4.29–9.59) 6.39 (4.24–9.62)
Folic acid supplement non-users (N = 1016)
No recommendation 3 % (18/525) 1.0 (ref) 1.0 (ref)
Do not use vitamins or supplements 2 % (2/99) 0.60 (0.14–2.62) 0.59 (0.13–2.61)
Use a multivitamin only 3 % (2/71) 0.83 (0.19–3.64) 0.85 (0.19–3.75)
Use vitamins and supplements 9 % (30/321) 2.94 (1.61–5.37) 2.88 (1.56–5.33)
Vitamin B12 supplement non-users (N = 984)
No recommendation 3 % (16/507) 1.0 (ref) 1.0 (ref)
Do not use vitamins or supplements 4 % (4/101) 1.30 (0.42–3.98) 1.31 (0.42–4.07)
Use a multivitamin only 4 % (3/69) 1.40 (0.40–4.93) 1.39 (0.39–4.95)
Use vitamins and supplements 14 % (43/307) 5.02 (2.77–9.10) 5.10 (2.78–9.37)
Calcium supplement non-users (N = 739)
No recommendation 9 % (38/403) 1.0 (ref) 1.0 (ref)
Do not use vitamins or supplements 7 % (5/71) 0.77 (0.29–2.03) 0.80 (0.30–2.13)
Use a multivitamin only 7 % (3/46) 0.70 (0.21–2.36) 0.65 (0.19–2.23)
Use vitamins and supplements 27 % (60/219) 3.80 (2.42–5.98) 3.56 (2.24–5.66)
Fish oil, EPA, omega-3, flaxseed or cod liver oil non-users (N = 880)
No recommendation 4 % (18/452) 1.0 (ref) 1.0 (ref)
Do not use vitamins or supplements 3 % (2/79) 0.61 (0.14–2.67) 0.72 (0.16–3.23)
Use a multivitamin only 3 % (2/62) 0.79 (0.18–3.48) 0.74 (0.17–3.31)
Use vitamins and supplements 7 % (21/287) 1.89 (0.99–3.61) 1.91 (0.99–3.69)
Glucosamine supplement non-users (N = 982)
No recommendation 1 % (6/508) 1.0 (ref) 1.0 (ref)
Do not use vitamins or supplements 1 % (1/91) 0.89 (0.11–7.47) 0.78 (0.09–6.71)
Use a multivitamin only 1 % (1/69) 1.20 (0.14–10.1) 1.21 (0.14–10.4)
Use vitamins and supplements 3 % (9/314) 2.46 (0.87–6.98) 2.36 (0.82–6.76)
a Started use defined as those consuming the supplement C once per week; Continued non-use are those consuming the supplement \ once per week
b Adjusted for age at baseline
c Adjusted for age at baseline, body mass index at baseline, race/ethnicity, education, menopausal status, and smoking status
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outcomes, as few data are available. In a prospective study of
1,038 patients with stage III colon cancer enrolled in the NCI-
sponsored Cancer and Leukemia Group B, Ng and colleagues
found no significant survival benefit to multivitamin use
during treatment [20]. In a review of 22 peer-reviewed stud-
ies, Greenlee et al. [19] concluded that ‘‘findings did not
support any conclusions regarding the effects of individual
antioxidant supplements during conventional breast cancer
treatment on toxicities, tumor response, recurrence, or sur-
vival.’’ Data from the Shanghai Breast Cancer Survival Study,
a large cohort of breast cancer patients with 532 recurrences
and 444 deaths, showed that use of vitamin E, vitamin C and
multivitamins by breast cancer patients was associated with
reduced risk of recurrence and survival, regardless of whether
use was during chemotherapy or not [21]. Because dietary and
lifestyle factors may differ between populations, it is unclear
as to whether these findings would apply to a mainly white,
U.S. population.
There are some limitations in our assessment of physi-
cian recommendations. We were unable to discern whether
discussions regarding multivitamin and/or supplement use
were initiated by physicians or by patients. In addition, the
question regarding recommendations from physicians only
referred to vitamins and supplements in general, not spe-
cific supplements such as antioxidants or those that showed
increases in use with chemotherapy. Furthermore, it did not
distinguish use of high-dose supplements versus meeting
recommended daily requirements. While a recommenda-
tion not to take any vitamins and supplements would
include antioxidants, a recommendation to use vitamins
and supplements may refer to other supplements than
antioxidants, such as B vitamins for neuropathy. However,
baseline non-users of vitamin C and E were more likely to
initiate use during treatment after receiving a recommen-
dation to use vitamins and supplements compared to those
receiving no recommendation. In this study, regular vita-
min C and E use, both before diagnosis and during treat-
ment, was relatively low. When stratified by physician
recommendation, sample sizes for some groups were small.
We have shown that patterns of use in this study are
impacted greatly by physician recommendations. The par-
ticipants in this clinical trial had ‘‘high-risk’’ Stage II or III
breast cancer with large tumors and/or nodal involvement.
Patients who enroll in a clinical trial may have more concerns
about their prognosis, or may have more reliance upon or
confidence in their oncologists, and this could influence the
lower use than that reported in the literature. Indeed, our
results show that supplement use was most likely to be
stopped when patients were advised by their physicians to
discontinue use. To our knowledge, this is the first study to
report upon patterns of supplement use during chemotherapy
in relation to recommendations from treating physicians, and
the first survey of these interactions between cancer patients
and their doctors. Thus, we are unable to compare our low
rates of use of supplements in relation to physician recom-
mendations to other published data on antioxidant use among
breast cancer patients. A major strength of our study is the
detailed assessment of multivitamin and supplement use at
multiple time points, specifically before diagnosis and dur-
ing breast cancer treatment. The majority of studies reporting
on supplement use by cancer patients are derived from data
ascertained at diagnosis, or several months following treat-
ment, with little information on patterns during chemother-
apy, which could be the most crucial time-point for effects on
treatment outcomes.
In this study, a number of participants did not discuss
supplement usage with their doctors. This would suggest
that better patient-physician communication is needed
although there are not clear empirical data upon which to
base suggestions regarding habits during chemotherapy.
With adequate followup time of patients enrolled in S0221,
and detailed information on use of multivitamins and
supplements before, during and after chemotherapy, data
upon which to base those recommendations will be avail-
able for advising patients on habits during cancer therapy.
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